Why Milestone Pharmaceuticals Stock Wilted on Wednesday

Milestone Pharmaceuticals reported just $238,000 in Cardamyst sales for the quarter, far below the more than $56 million analyst consensus, while its net loss widened to over $26 million, or $0.20 per share. Commercial spending rose 52% year over year as the newly launched FDA-approved nasal spray only had about 600 scripts filled by the end of April. The company still has nearly $184 million in cash and says it has runway into the second half of 2027, but the launch disappointment weighed on shares, which fell more than 9%.

Analysis

The market is punishing MIST not because one quarter was weak, but because the launch curve is already being read as a proxy for physician pull-through and payer willingness. For a single-asset biotech, that matters more than the reported loss: if initial prescribing velocity is this soft, every month of under-penetration increases the probability of a downward revision to the 2026/27 adoption model and raises the chance of a financing overhang even before cash runway becomes mathematically tight.

The second-order issue is commercial efficiency, not just demand. A launch that requires materially higher SG&A to generate minimal scripts suggests the company is fighting an education/friction problem in a niche acute-care workflow, where usage depends on ER/cardiology awareness and easy formulary access. That creates a classic biotech negative flywheel: weak uptake forces higher spend, higher spend widens losses, and wider losses pressure investor confidence, which can compress valuation long before the drug’s clinical optionality is fully tested.

The contrarian case is that the first 60-90 days of a launch in a specialized indication can be a poor read-through if access and habit formation lag. If payer coverage broadens, specialty sales reps get traction, or early prescribers become repeat users, the script trajectory can inflect sharply over the next two quarters. But absent evidence of a step-up in refill behavior and new account activation by the next update, the base case should remain one of prolonged multiple compression rather than an immediate recovery.

From a trading perspective, this is more attractive as a tactical short on failed-launch sentiment than as a structural long. The cleanest expression is a short into any relief bounce, with the key catalyst being the next quarterly script/guide update; if management cannot show acceleration, downside likely comes from both lower terminal revenue assumptions and a higher perceived probability of dilution. Because the balance sheet buys time, the trade is not about bankruptcy risk — it is about valuation reset via slower adoption and a higher cost of capital.

Key Decisions for Investors

• Short MIST on any 5-10% rebound over the next 1-2 weeks; target a 15-25% downside move if the market concludes launch momentum is not inflecting.
• For defined risk, buy MIST puts 1-2 expiries out with strikes ~10-15% below spot; this captures the next script print / guidance update without unlimited borrow risk.
• If already long, reduce position size by 50% and wait for evidence of script acceleration or payer expansion; the risk/reward now favors capital preservation over averaging down.
• Pair trade: short MIST versus a diversified commercial-stage biotech basket or broader XBI exposure to isolate failed-launch risk from sector beta.
• Avoid new long entries until management shows sequential growth in prescriptions and lower SG&A intensity for at least one quarter; otherwise the name remains a dead-money overhang despite the cash runway.